Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
Georgina V. Long(The University of Sydney), F. Stephen Hodi(Harvard University), Olivier Michielin(SIB Swiss Institute of Bioinformatics), Robert Hans Ingemar Andtbacka(University of Utah), Jeffrey Chou(Amgen (United States)), Jonathan Cebon(La Trobe University), Eugenio Fernández(Hôpital Beau-Séjour), Ari M. Vanderwalde(West Cancer Center), Christine K. Gause(Merck & Co., Inc., Rahway, NJ, USA (United States)), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Josep Malvehy(Universitat de Barcelona), Abraham Anderson(Amgen (United States)), Anthony J. Olszanski(Fox Chase Cancer Center), Antoni Ribas(University of California, Los Angeles), Thomas F. Gajewski(University of Chicago), David R. Kaufman(Gates (United States)), Reinhard Dummer(University Hospital of Zurich), John M. Kirkwood(UPMC Hillman Cancer Center), Kevin Gorski(Amgen (United States)), Lisa Chen(Amgen (United States))
Cited by 110
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k